Sodium-alginate microparticles with permeation enhancers achieved over 80% insulin encapsulation efficiency and significantly improved insulin transport across intestinal cells in laboratory tests.
>80% encapsulation efficiencyThe alginate microparticles successfully trapped over 80% of loaded insulin and protected it through simulated stomach conditions before releasing it at intestinal pH
What the researchers found
The sodium-alginate microparticles achieved encapsulation efficiency above 80% across all formulations, meaning the vast majority of insulin was successfully trapped inside the beads. The pH-responsive alginate polymer protected insulin in acidic conditions (mimicking the stomach) and released it at higher pH (mimicking the intestine).
After 120 minutes in simulated intestinal fluid containing digestive enzymes, 66% of the insulin remained intact — a meaningful improvement over unprotected insulin. Permeability testing using Caco-2 intestinal cell models showed that formulations containing the surfactant-based permeation enhancers (Labrasol ALF and Labrafil M 2125 CS at 0.10% v/v) significantly increased insulin transport across the cell layer compared to a control insulin solution.
Why it matters
Millions of people with diabetes inject insulin daily, which is painful, inconvenient, and reduces treatment adherence. An effective oral insulin formulation would be transformative for diabetes management. This study demonstrates a practical approach using safe, well-known materials (alginate, food-grade surfactants) that protect insulin through the stomach and enhance its absorption in the intestine.
How the study worked
Researchers formulated sodium-alginate microparticles loaded with insulin using an ionotropic gelation method. They incorporated two nonionic surfactant-based permeation enhancers (Labrasol ALF and Labrafil M 2125 CS) at 0.10% concentration, individually and in combinations. The microparticles were evaluated for encapsulation efficiency, in vitro drug release at different pH levels, enzymatic stability in simulated intestinal fluid (SIF), and permeability across Caco-2 cell monolayers (a standard model of the intestinal barrier).
What this study cannot tell us
All testing was performed in vitro (in laboratory dishes), not in living animals or humans. Caco-2 cell models, while standard, are simplified representations of the intestinal wall and don't account for mucus layers, gut motility, or the full complexity of the GI tract. The 66% insulin survival after enzymatic exposure means a third of the insulin was still lost. No in vivo bioavailability or blood glucose-lowering data were reported.
How to read the evidence
This is an in vitro laboratory study testing a novel drug delivery formulation. While the results are promising, no animal or human testing has been performed, placing this at an early preclinical stage of evidence.
When this study was published
Published in late 2023, this study represents recent work in the active field of oral peptide delivery research. The techniques and materials used reflect current pharmaceutical technology approaches.
The bigger picture
Oral peptide delivery is one of the biggest challenges in pharmaceutical science. The success of oral semaglutide (Rybelsus) proved it's possible to get a peptide drug through the gut, but insulin is a much larger and more fragile molecule. This study joins a large body of research exploring different encapsulation strategies — alginate-based systems are attractive because alginate is biocompatible, inexpensive, and already used in food and medicine. The combination approach of pH-responsive protection plus permeation enhancement represents the current thinking in the field.
Questions still open
- Would these alginate microparticles maintain their protective effect and insulin release profile in animal models with real GI conditions?
- How does the 66% enzymatic survival rate translate to actual blood glucose reduction when tested in vivo?
- Could this formulation approach be combined with other strategies like enteric coating to further improve insulin protection and absorption?
Common questions
Why can't you just swallow an insulin pill right now?
How close are we to having oral insulin available?
Read the original research
Formulation and Evaluation of Insulin-Loaded Sodium-Alginate Microparticles for Oral Administration.
Pharmaceutics, 16(1)
Citation
Bácskay, Ildikó; Papp, Boglárka; Pártos, Péter; Budai, István; Pető, Ágota; Fehér, Pálma; Ujhelyi, Zoltán; Kósa, Dóra. (2023). Formulation and Evaluation of Insulin-Loaded Sodium-Alginate Microparticles for Oral Administration.. Pharmaceutics, 16(1). https://doi.org/10.3390/pharmaceutics16010046